Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Pulse Biosciences (PLSE) Other financing activities (2023 - 2024)

Pulse Biosciences has reported Other financing activities over the past 2 years, most recently at $59000.0 for Q4 2024.

Quarterly results put Other financing activities at $59000.0 for Q4 2024, up 883.33% from a year ago — trailing twelve months through Dec 2025 was $3000.0 (down 25.0% YoY), and the annual figure for FY2024 was $281000.0, up 4583.33%.
Other financing activities for Q4 2024 was $59000.0 at Pulse Biosciences, up from -$56000.0 in the prior quarter.
Over the last five years, Other financing activities for PLSE hit a ceiling of $59000.0 in Q4 2024 and a floor of -$56000.0 in Q3 2024.